Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Funding Agency
For Profit
(FP)
739.7M Funding
616 People
1645 Grants
People
Conrad Clemens
Health Promotion Sciences
Senior Associate Dean
Abhijeet Kumar
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Aaron Scott
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Rachna Shroff
Medicine
Professor
Elena Young
College of Medicine - Phoenix
Research Compliance Manager II
Mason Burchfield
College of Medicine - Phoenix
Research Compliance Administrator III
Kirsten Anderson
Az Health Sciences Division
Research Compliance Administrator IV
Franz Rischard
Medicine
Professor
Sasha Taleban
Medicine
Associate Professor
Gustavo Cornejo
Az Health Sciences Division
Research Compliance Administrator III
Recent Grants
Adapting to Temporal Patterns in A/B Testing
Active
·
2025
·
$100K
CFG-DermatologyFellowship-2024
Active
·
2025
·
$95K
Inflammatory Bowel Disease (IBD) West Case Conference
Active
·
2025
·
$20K
Inflammatory Bowel Disease (IBD) West Case Conference
Active
·
2025
·
$10K
Boehringer Ingelheim Veterinary Scholars Program (VSP) 2025
Active
·
2025
·
$7.7K
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated
Active
·
2024
·
$7.5M
A Phase 1/2 Open-Label, Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Gastroesophageal Cancer: Master (KE
Active
·
2024
·
$4.5M
Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial FACILE VT Trial
Active
·
2024
·
$3.5M
A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
Active
·
2024
·
$2.2M
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Active
·
2024
·
$1.6M
